Recursion Pharmaceuticals (RXRX) Expected to Post Earnings on Wednesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is projected to post its Q3 2026 & Study Update results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.2190) per share and revenue of $14.81 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 & Study Update earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same quarter last year, the company earned ($0.41) EPS. On average, analysts expect Recursion Pharmaceuticals to post ($0.93) EPS for the current fiscal year and ($0.87) EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $4.05 on Wednesday. The company has a 50-day simple moving average of $3.69 and a 200-day simple moving average of $3.55. The firm has a market capitalization of $2.17 billion, a P/E ratio of -3.89 and a beta of 1.04. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $6.25.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 22,408 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. The trade was a 1.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the sale, the director directly owned 6,108,287 shares in the company, valued at approximately $29,564,109.08. This represents a 0.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 157,408 shares of company stock valued at $643,576. 6.65% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of recent research reports. Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a research report on Friday, October 16th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.18.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.